


Name	Prof. Dr. med. Robert Zeiser	
Current Position	W3 Professor & Director, Division of Tumor immunology, University Hospital Freiburg	
Country	Germany	
Major Field	GVHD biology and therapy	

Educational Background

Academic Education

Since 06/19	W3 Professor & Director, Division of Tumor immunology, University Hospital Freiburg
Since 09/13	W3-Professor, Medical Faculty, Albert-Ludwigs Universität Freiburg
2005-2007	Post-Doctoral Research Fellow, Department of BMT (Prof. Negrin) at Stanford University, Stanford, USA
2001-2004	Residency/Fellowship (Internal Med. & Hematology/Oncology), UKL Freiburg, Germany
10/95-10/01	Medical School, Albert-Ludwigs Universität Freiburg

Scientific and Academic Degrees

2010	Habilitation for Internal Medicine, Albert-Ludwigs Universität Freiburg, 2010
2001	Doctorate, Department of Pathology, Albert-Ludwigs Universität Freiburg

Professional Experience

Transplant physician, clinical and preclinical studies on GVHD biology and therapy

Other Experience and Professional Memberships

Scientific activities

Since 2021	Speaker of SFB1479 “Oncogene driven immune escape”
Since 2018	Member in the Board of Directors of SFB 1160
Since 2017	Member in the Board of Directors of TRR 167
Since 2016	Associate Editor of the Journal <i>Blood</i> ; American Society of Hematology
Since 2014	Deputy Director of the SFB 850
Reviewer for:	Science, Nature Medicine, Nature Immunology, Nature Reviews Cancer, Cancer Discovery NEJM, Lancet Haematol.
Reviewer for funding agencies:	DFG, ERC, Wissenschaftsrat, Cancer Research UK, ANR, Schweizer Krebsliga

Main Scientific Publications

Selected publications

- Zeiser R**, Polverelli N, Ram R, Hashmi SK, Chakraverty R, Middeke JM, Musso M, Giebel S, Uzay A, Langmuir P, Hollaender N, Gowda M, Stefanelli T, Lee SJ, Teshima T, Locatelli F; REACH3 Investigators. Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease. *N Engl J Med*. 385(3): 228-238, 2021
- Zeiser R**, von Bubnoff N, Butler J, Mohty M, Niederwieser D, Or R, Szer J, Wagner EM, Zuckerman T, Mahuzier B, Xu J, Wilke C, Gandhi KK, Socié G; REACH2 Trial Group. Ruxolitinib for Steroid-Refractory Acute Graft-Versus-Host Disease. *New England Journal of Medicine* 2020, 382:1800-1810
- Prestipino A, Emhardt A, Aumann K, O’Sullivan D, Gorantla SP, Duquesne S, Melchinger W, Braun L, Vuckovic S, Boerries M, Busch H, Halbach S, Pennisi S, Poggio T, Apostolova P, Veratti P, Hettich M, Niedermann G, Bartholomä M, Shoumariyeh K, Jutzi J, Wehrle J, Dierks C, Becker H, Schmitt-Graeff A, Follo

- M, Pfeifer D, Rohr J, Fuchs S, Ehl S, Hartl FA, Minguet S, Miething C, Heidel F, Kröger N, Trivai I, Brummer T, Finke J, Illert AL, Ruggiero E, Bonini C, Duyster J, Pahl HL, Lane SW, Hill GR, Blazar BR, Bubnoff N, Pearce EL, **Zeiser R**. Oncogenic JAK2V617F causes PD-L1 expression mediating immune-escape in myeloproliferative neoplasms. *Science Translational Medicine* 10 (429), 2018
4. Mathew NR, Baumgartner F, Braun L, David O'Sullivan, Thomas S, Waterhouse M, Müller TA, Hanke K, Taromi S, Apostolova P, Illert AL, Melchinger W, Duquesne S, Schmitt-Graeff A, Osswald L, Yan K-L., Weber A, Tugues S, Spath S, Pfeifer D, Follo M, Claus R, Lübbert M, Rummelt C, Bertz H, Wäsch R, Haag J, Schmidts A, Schultheiss M, Bettinger M, Thimme R, Ullrich E, Tanriver Y, Vuong GL, Arnold R, Hemmati P, Wolf D, Ditschkowski M, Jilg C, Wilhelm K, Leiber C, Gerull S, Halter J, Lengerke C, Pabst T, Schroeder T, Kobbe G, Rösler W, Doostkam S, Meckel S, Stabla K, Metzelder SK, Halbach S, Brummer T, Hu Z, Dengjel J, Hackanson B, Schmid C, Holtick U, Scheid C, Spyridonidis A, Stölzel F, Ordemann F, Müller LP, Sicrede-Fontbrune F, Ihorst G, Kuball J, Ehler J, Feger D, Wagner EV, Cahn JY, Schnell J, Kuchenbauer F, Bunjes D, Chakraverty R, Richardson S, Gill S, Kröger N, Ayuk F, Vago L, Ciceri F, Müller AM, Kondo T, Teshima T, Klaeger S, Kuster B, Kim D, Weisdorf D, van der Velden W, Dörfel D, Bethge W, Hilgendorf I, Hochhaus A, Andrieux G, Bories M, Busch H, Magenau J, Reddy P, Labopin M, H. Antin J, Henden AS, Hill GR, Kennedy GA, Bar M, Sarma A, McLornan D, Mufti G, Oran B, Rezvani K, Sha O, Negrin RS, Nagler A, Prinz M, Burchert A, Neubauer A, Beelen D, Mackensen A, von Bubnoff N, Herr W, Becher B, Socié G, Caligiuri MA, Ruggiero E, Bonini C, Häcker G, Duyster J, Finke J, Pearce E, Blazar BR, **Zeiser R**. Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD mutant leukemia cells. *Nature Medicine* 24: 282-291, 2018
 5. Hülsmüller J, Ottmüller KJ, Neeff HP, Koyama M, Gao Z, Thomas OS, Follo M, Al-Ahmad A, Prinz G, Duquesne S, Dierbach H, Kirschnek S, Lämmermann T, Blaser MJ, Fife BT, Blazar BR, Beilhack A, Hill GR, Häcker G, **Zeiser R**. Neutrophils provide cellular communication between ileum and mesenteric lymph nodes at graft-versus-host disease onset. *Blood*. 131:1858-1869, 2018
 6. **Zeiser R**, Blazar B. Acute Graft-versus-Host Disease - Advances in Biology, Prevention and Therapy. *The New England Journal of Medicine* 377(22):2167-2179, 2017
 7. **Zeiser R**, Blazar BR. Chronic graft-versus-host disease Diagnosis, Prognosis and Novel therapeutic targets. *The New England Journal of Medicine* 377(26):2565-2579, 2017
 8. Schwab L*, Goroncy*, L. S. Palaniyandi S, S. Gautam, A. Triantafyllopoulou, A. Mocsai, W. Reichardt, F.J. Karlsson, S.V. Radhakrishnan, K. Hanke, A. Schmitt-Gräff, M. Freudenberg, F.D. von Loewenich, P. Wolf, F. Leonhardt, N. Baxan, D. Pfeifer, O. Schmah, A. Schönle, S.F. Martin, R. Mertelsmann, J. Duyster, J. Finke, M. Prinz, P. Henneke, H. Häcker, Hildebrandt, G.C., Häcker* G.*, **Zeiser R***. Neutrophil granulocytes recruited upon translocation of intestinal bacteria enhance GvHD via tissue damage. *Nature Medicine* 20: 648-54, 2014
 9. Yaktapour N, Meiss F, Mastroianni J, Zenz T, Andriova H, Mathew NR, Claus R, Hutter B, Frohling S, Brors B, Pfeifer D, Pantic M, Bartsch I, Spehl TS, Meyer PT, *Duyster J, *Zirlik K, *Brummer T, ***Zeiser R**. BRAF inhibitor-associated ERK activation drives development of chronic lymphocytic leukemia. *J Clin Invest* 124, 5074-5084, 2014
 10. Jankovic D, Ganesan J, Bscheider M, Stickel N, Weber FC, Guarda G, Follo M, Pfeifer D, Tardivel A, Ludigs K, Bouazzaoui A, Kerl K, Fischer JC, Haas T, Schmitt-Gräff A, Manoharan A, Müller L, Finke J, Martin SF, Gorka O, Peschel C, Ruland J, Idzko M, Duyster J, Holler E, French LE, *Poeck H, *Contassot E, ***Zeiser R**. The Nlrp3 inflammasome regulates acute graft-versus-host disease. *J Exp Med* 210, 1899-1910, 2013.
 11. Wilhelm K, Ganesan J, Müller T, Dürr C, Grimm M, Beilhack A, Krempel CD, Sorichter S, Gerlach UV, Jüttner E, Zerweck A, Gärtner F, Pellegatti P, Di Virgilio F, Ferrari D, Kambham N, Fisch P, Finke J, *Idzko M, ***Zeiser R**. Graft-versus-host disease is enhanced by extracellular ATP activating P2X(7)R. *Nature Medicine* 12, 1434-1438, 2010

*contributed equally